Annual results moved from a peak in 2022 to a trough in 2024 and a recovery in 2025. Revenue fell from KRW 543.8 billion in 2022 to KRW 522.7 billion in 2023 (down 3.9% year on year) and KRW 507.4 billion in 2024 (down 2.9%), then rose to KRW 535.1 billion in 2025 (up 5.5%).
Among 2022 to 2025, 2022 was the largest year and 2024 the smallest. Operating profit fell from KRW 28.5 billion in 2022 to KRW 12.6 billion in 2023 (down 55.9%) and KRW 539 million in 2024 (down 95.7%), then recovered to KRW 3.29 billion in 2025 (up 511.2%).
The operating margin dropped from 5.2% in 2022 to 0.1% in 2024 before edging up to 0.6% in 2025.
Net income attributable to controlling shareholders swung from KRW 10.7 billion in 2022 to a net loss of KRW 28.8 billion in 2023 and a larger net loss of KRW 52.6 billion in 2024, narrowing to a net loss of KRW 2.15 billion in 2025, which marks three consecutive loss years since 2023.
Net income including non-controlling interests followed the same direction, from KRW 10.6 billion in 2022 to a net loss of KRW 2.24 billion in 2025. Operating cash flow was KRW 30.5 billion in 2022 and KRW 36 billion in 2023, turned negative at KRW 2.79 billion in 2024, and recovered to KRW 3.98 billion in 2025.
On a quarterly basis, net income attributable to controlling shareholders of KRW 7.94 billion in 4Q 2025 turned into a net loss of KRW 8.55 billion in 1Q 2026. Revenue bottomed at KRW 135.4 billion in 1Q 2026 and rose to KRW 140.7 billion in 2Q and KRW 142.4 billion in 3Q.
Newly licensed anticancer drugs, Ketotop and the glucose monitor were cited as drivers of the 3Q 2026 operating profit gain. Quarterly revenue was also weighed by the end of a flu vaccine business that had contributed in the prior-year period. The main reason for the bottom-line loss is the financial segment.
Cumulative financial losses through 3Q 2026 were about KRW 26.1 billion in the preliminary release, a deterioration of about KRW 27.5 billion from the prior-year period, according to one analysis. Quarterly results swing widely, so a single quarter is too early to read as a trend.